A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata
A Phase I/II Study Of The Efficacy,Safety and Pharmacokinetics Of Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Alopecia Areata
In the register
The register attaches this trial to Jaktinib (Suzhou Zelgen Biopharmaceuticals), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Status unknown
- Declared phase
- Phase 1/2
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Participants (registry)
- 160
- Start
- August 2020
- Primary completion
- December 2024
- Study completion
- December 2024
- Last registry update
- March 2024
- Countries
- China
Conditions studied: Alopecia Areata(AA)
Interventions: Jaktinib hydrochloride cream, Jaktinib, Placebo
Other trials of Jaktinib
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.